Condition (MeSH)
Eye Pain
ClinicalTrials.gov lists 29 trials for Eye Pain or a narrower condition beneath it. Sylentis, S.A. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
29 of the 29 trials are tagged with Eye Pain itself; the rest are tagged with a narrower condition beneath it.
When did Eye Pain trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Eye Pain trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 1 |
| Phase 4 | 5 |
| Not applicable | 8 |
| Observational | 3 |
How many Eye Pain trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 19 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Eye Pain trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sylentis, S.A. | 3 |
| Biogen | 2 |
| EyeCool Therapeutics, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| Bausch & Lomb Incorporated | 1 |
Showing 5 of 7 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SYL1001 | 3 |
| Dextenza 0.4Mg Ophthalmic Insert | 3 |
| Prednisolone Acetate 1% Oph Susp | 2 |
| Vehicle Ophthalmic Solution | 2 |
| SAF312 | 2 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Eye Pain trials report? (9)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Spinal compression fracture | 2 | 1 |
| Cerebrovascular accident | 1 | 1 |
| Diverticulum | 1 | 1 |
| Gastrointestinal haemorrhage | 1 | 1 |
| Haemorrhagic cerebral infarction | 1 | 1 |
Showing 5 of 9 adverse events.
Which publications cover Eye Pain? (75)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Post-Intravitreal injection pain reduction using topical NSAIDS: A comparative study. | European journal of ophthalmology | 2025 | Yes |
| Pharmacological therapy for relieving pain in panretinal photocoagulation: A network meta-analysis of randomized controlled trials. | Survey of ophthalmology | 2025 | Yes |
| COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN. | Retina (Philadelphia, Pa.) | 2024 | Yes |
| Short-Term Topical Tetracaine Is Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: A Double-Blind, Randomized Clinical Trial. | Annals of emergency medicine | 2021 | Yes |
| Intraoperative Pain Sensation During Cataract Surgery: Why Does Timing Matter? | Current eye research | 2021 | Yes |
Showing 5 of 75 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.